Jim Cramer: Why It Doesn't Matter How Much Amgen Paid for Otzela

Author:
Publish date:
Video Duration:
0

Jim Cramer breaks down Amgen's (AMGN) - Get Report deal to buy Otezla's rights from Celgene (CELG) - Get Report . 

Real Money Stock of the Day Amgen announced Monday morning that it was acquiring the rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash.

"The acquisition of Otezla offers a unique opportunity for Amgen to provide patients an innovative oral therapy for psoriasis and psoriatic arthritis that fits squarely within our portfolio and complements our Enbrel and AMGEVITA brands," Amgen CEO Robert Bradway said in a statement.

Jim Cramer breaks down what the deal means for Amgen and Bristol-Myers (BMY) - Get Report  pending merger with Celgene.

"So suddenly they get Otezla. I don't care if they paid $9 billion or $12 billion or $14 billion, I don't care. And they paid $11.2 billion, plus the present value of the stream at a total of $13 billion and change," said Cramer. 

More from Cramer Today

Full Replay: Jim Cramer Weighs In on Amgen's Deal, Salesforce and U.S.-China Trade War

Jim Cramer: Pajama Traders Make Us All Look Stupid

Jim Cramer: Why It Doesn't Matter If China Actually Called Trump

Jim Cramer: How to Trade Salesforce During the U.S.-China Trade War

Premium Pick: 4 Tips for Dealing With Volatility on Trump, China and the Fed

Subscribe to our Youtube Channel for more videos : Listen our latest Podcasts on Soundcloud

Jim Cramer and TheStreet Launch Bull Market Fantasy Channel on Maven

Jim picks stocks on Wall Street, now he's picking NFL players for fantasy football! Check it out at BullMarketFantasy.com - check it out here or see his latest videos below:

Cramer Confessional: Jim Cramer's One Fantasy Drafting Regret

Cramer's Fantasy Football Draft Got a Little Crazy - Watch

Jim Cramer Breaks Down His Top Lesson From His Fantasy Draft

Catch Up: Today's Top News Videos Below